1 June 2018 - Tesaro's ovarian cancer drug Zejula (niraparib), the first PARP inhibitor shown to be effective in patients with a BRCA mutation as well as those without a BRCA mutation, has been accepted onto the Cancer Drugs Fund.

Because overvall survival data for Zejula is not yet available, NICE has recommended the drug via the Cancer Drugs Fund for women with a BRCA mutation who have received two lines of chemotherapy and in women without a BRCA mutation who have received two or more lines of chemotherapy, while further data is collected.

"Recurrent ovarian cancer is an aggressive form of cancer where a key goal of treatment is to keep women in remission and off chemotherapy for as long as possible - allowing them the best chance for a good quality of life," said Jonathan Ledermann, Professor of Medical Oncology at the University College London Cancer Institute. "Zejula offers the chance to delay this cancer from returning or progressing for months, and possibly years in some cases. It is a significant step forward. Crucially, this decision opens the door for many women who, until now, have not had the option of maintenance treatment with a PARP inhibitor."

Read Pharma Times article